Menu Back to Continuing-Education

Continuing Education

DIA 2025 brings together key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the globe and across all disciplines involved in the discovery, development, and lifecycle management of healthcare products. DIA 2025 is intended to strengthen professionals' understanding of cross-cutting concepts in biopharmaceutical development and foster collaboration across disciplines for better health outcomes.

Learning Objectives:

At the conclusion of the DIA 2025 Global Annual Meeting, participants should be able to:

Explain the application of emerging technologies and frameworks in pharmacovigilance to analyze safety signals, assess benefit-risk outcomes, and manage patient safety effectively
Illustrate innovative clinical trial designs, such as decentralized and AI-driven models, to enhance participant diversity, employ retention strategies, and evaluate operational efficiency
Demonstrate the use of real-world data and AI technologies to analyze regulatory challenges, organize data-driven insights, and justify decisions across the medical product development lifecycle
Translate technological innovations into improved medical communications, describe strategies to enhance health literacy, and appraise methods to foster resilience in regulatory writing practices
Categorize patient experience data and design inclusive trial frameworks that integrate diverse perspectives, ensuring improved accessibility and equity in global medical product development
Apply advanced regulatory frameworks and create innovative approaches to diagnose rare biomarkers and develop personalized therapies with regulatory compliance
Organize adaptive project management frameworks, compare global development strategies, and evaluate portfolio optimization to ensure successful project execution and patient access
Use risk-based quality management practices and illustrate AI-driven tools to analyze compliance challenges, differentiate risks, and enhance data integrity in clinical trials
Classify global regulatory strategies, propose methodologies for engaging regulators, and evaluate the integration of patient input to enhance medical product approval processes
Plan collaborative approaches, differentiate between reliance models, and formulate innovative solutions to streamline CMC processes and maintain product quality
Outline statistical methodologies, interpret Bayesian approaches, and justify the use of real-world evidence in optimizing trial designs and regulatory submissions
Develop inclusive leadership strategies, assess the impact of mentorship programs, and practice utilizing generative AI tools to enhance communication, decision-making, and organizational growth

Specific learning objectives for each offering can be found on the DIA 2025 website under the program schedule.

Select short courses and program offerings (including sessions, forums, and workshops) may be approved for AMA PRA Category 1 Credits™, pharmacy or nursing contact hours, Project Management Institute (PMI) professional development units (PDUs), or International Accreditors for Continuing Education and Training (IACET) continuing education units (CEUs). Continuing education credit information will be clearly identified on the DIA 2025 website with the statement CME, Pharmacy, Nursing, or PMI PDUs. CE credits are not available for the Opening Plenary and Keynote Address, Innovation Theater presentations, Content Hubs, Community Rounds, Posters, and Sponsored events.

View instructions for requesting CE credits

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DIA. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 39.25 (25.75 for the Short Courses and 13.5 for the Annual Meeting Sessions) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 39.25 contact hours (25.75 for the Short Courses and 13.5 for the Annual Meeting Sessions). California Board of Registered Nursing, Provider Number 13485, approved for 39.25 contact hours.

Accreditation Council for Continuing Medical Education (ACCME)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and the Drug Information Association (DIA). PIM is accredited by the ACCME to provide continuing medical education for physicians.
Accreditation Council for Pharmacy Education (ACPE)

DIA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. This program is designated for up to 39.25 contact hours or 3.925 continuing education units (CEU’s), (25.75 contact hours or 2.575 CEUs for the Short Courses and 13.5 contact hours or 1.35 CEUs for the Annual Meeting Sessions).
ACPE Credit Requests MUST BE SUBMITTED by Friday, August 1, 2025. DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. If ACPE credit is not requested by Friday, August 1, 2025, the CEU request will not be transmitted through to the CPE Monitor. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit.
American Nurses Credentialing Center (ANCC)
PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DIA has been reviewed and approved as a provider of project management training by the Project Management Institute (PMI).
Participants may receive up to 6.74 professional development units (PDUs), (2.75 PDUs for the Short Course and 4 PDUs for the Annual Meeting Sessions) for attending the Annual Meeting program offerings. All approved DIA designated PMI numbers for approved offerings are found on the DIA 2025 Global Annual Meeting website on each designated offering description.

The PMI Registered Education Provider logo is a registered mark of the Project Management Institute, Inc.
International Accreditors for Continuing Education and Training (IACET)

Drug Information Association (DIA) is accredited by the International Accreditors for Continuing Education and Training (IACET) and offers IACET CEUs for its learning events that comply with the ANSI/IACET Continuing Education and Training Standard. IACET is recognized internationally as a standard development organization and accrediting body that promotes quality of continuing education and training.

As an IACET Accredited Provider, DIA offers CEUs for its programs that qualify under the ANSI/IACET Standard. DIA is authorized by IACET to offer up to 2.1 CEUs (.3 CEUs for each short course) for this program.

IACET credit available for virtual Short Courses only.
Continuing Legal Education

For attorneys who would like to receive continuing legal education credits for attending DIA 2025, please complete your state’s application for credit and submit accordingly. If you require additional information, please contact CE@DIAglobal.org.
CE Credit Allocation

Pre-Conference Short Courses – June 9, through June 15, 2025

Half-day short courses:
(9:30 AM – 12:30 PM) Up to 2.75 AMA PRA Category 1 Credits™, or 2.75 pharmacy contact hours or .275 CEUs, or 2.75 nursing contact hours, or .3 IACET CEUs

(1:00 PM – 4:00 PM) Up to 2.75 AMA PRA Category 1 Credits™, or 2.75 pharmacy contact hours or .275 CEUs, or 2.75 nursing contact hours, 2.75 PMI PDUs, or .3 IACET CEUs

Full-day short courses:
(9:00 AM – 5:00 PM) Up to 6.5 AMA PRA Category 1 Credits™, or 6.5 pharmacy contact hours or .65 CEUs, or 6.5 nursing contact hours, or 6.5 PMI PDUs

Annual Meeting Program Offerings – June 16-19, 2025
Up to 13.5 AMA PRA Category 1 Credits™, or 13.5 pharmacy contact hours or .135 CEUs, or 13.5 nursing contact hours, or 4 PMI PDUs
Statements of Credit
Participants who would like to receive continuing education credit for DIA 2025 must scan their DIA name badge at each offering to record their attendance. Participants must scan their badges within 15 minutes of the start of the of the offerings. Participants who do not scan their badges within the allotted time will not be eligible to request the available continuing education credits for that offering. If a participant attends multiple offerings within the same timeframe, only the last scanned entry will be recorded.

If you would like to receive a statement of credit for the sessions you attend the conference, you must request CE credit online through My Transcript available on Thursday, June 26, 2025 (see instructions below). Participants will be able to download a statement of credit upon successful submission of the credit request.

To access My Transcript:
- Visit DIAglobal.org,
- Sign In with your DIA User ID and Password
- Select the Welcome Menu in the upper right hand corner (where your name appears)
- Select My Account from the menu
- Select My Transcript then Manage My Transcripts available on Thursday, June 26, 2025
- ACPE credit requests must be submitted by Friday, August 1, 2025
Disclaimer

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the DIA. Speakers, agenda, and CE information are subject to change without notice.

Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.
Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) and DIA require faculty, planners, managers and other individuals who are in a position to control the content of this activity to disclose all their financial relationships with ineligible companies. They may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and mitigated by PIM and DIA according to PIM policy for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Disclosure statements will be included on a slide in each meeting room, as well as on the DIA 2025 website.
Americans with Disabilities Act (ADA)

Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.